June 23, 2020 / 11:31 AM / 11 days ago

BRIEF-Karuna Announces Positive Outcome Of End-Of-Phase 2 Meeting With FDA For Karxt For Schizophrenia

June 23 (Reuters) - Karuna Therapeutics Inc:

* KARUNA THERAPEUTICS ANNOUNCES POSITIVE OUTCOME OF END-OF-PHASE 2 MEETING WITH THE FDA FOR KARXT FOR THE TREATMENT OF ACUTE PSYCHOSIS IN PATIENTS WITH SCHIZOPHRENIA

* KARUNA THERAPEUTICS INC - ON TRACK TO INITIATE PHASE 3 PROGRAM, INCLUDING EFFICACY AND OPEN-LABEL LONG-TERM SAFETY TRIALS, BY END OF 2020

* KARUNA THERAPEUTICS - IN PHASE 2 TRIAL, KARXT DEMONSTRATED ROBUST EFFICACY ON PRIMARY AND KEY SECONDARY OUTCOME MEASURES AND WAS WELL TOLERATED

* KARUNA THERAPEUTICS - PLANS TO INITIATE 2 INPATIENT TRIALS EVALUATING EFFICACY OF KARXT FOR TREATMENT OF ACUTE PSYCHOSIS IN ADULTS WITH SCHIZOPHRENIA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below